Octreotide and celecoxib synergistically encapsulate VX2 hepatic allografts following transcatheter arterial embolisation

Tong,Huan; Li,Xiao; Zhang,Chun-Le; Gao,Jin-Hang; Wen,Shi-Lei; Huang,Zhi-Yin; Tang,Cheng-Wei

doi:10.3892/etm.2013.897

Octreotide and celecoxib synergistically encapsulate VX2 hepatic allografts following transcatheter arterial embolisation

Authors:
- Huan Tong
- Xiao Li
- Chun-Le Zhang
- Jin-Hang Gao
- Shi-Lei Wen
- Zhi-Yin Huang
- Cheng-Wei Tang
View Affiliations

Affiliations: Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, P.R. China, Division of Peptides Related with Human Diseases, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, P.R. China
Published online on: January 16, 2013 https://doi.org/10.3892/etm.2013.897
Pages: 777-782

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To evaluate the encapsulation of VX2 hepatic allografts in rabbits induced by octreotide and celecoxib administration following transcatheter arterial embolisation (TAE), rabbits with hepatic VX2 allografts were divided into four groups: control, TAE, octreotide + celecoxib (O+C) and the multimodality therapy (TAE+O+C). Allograft metastasis, capsule thickness and percentage of clear cells were measured and vascular endothelial growth factor (VEGF) and CD31 were detected by immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) analysis. The extrahepatic metastases of each intervention group were significantly fewer than those of the control group, with the TAE+O+C group exhibiting the fewest extrahepatic metastases. The TAE+O+C group had the greatest proportion of clear cells and thickest capsule on day 30. Increased capsule thickness was negatively correlated with tumour metastasis. In addition, VEGF expression levels assessed by immunohistochemistry and RT-PCR in the three intervention groups were significantly lower than those in the control group. Furthermore, the TAE+O+C group had a significantly reduced CD31 count induced by TAE. These results demonstrate that TAE, followed by long-term administration of octreotide and celecoxib, synergistically inhibits VX2 hepatic allograft metastasis by increasing the proportion of clear cells, promoting encapsulation and inhibiting angiogenesis.

View Figures

View References

1.	Bruix J and Llovet JM: Major achievements in hepatocellular carcinoma. Lancet. 373:614–616. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Shah SA, Greig PD, Gallinger S, et al: Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg. 202:275–283. 2006. View Article : Google Scholar : PubMed/NCBI
3.	Lee EH, Kao WWY and Schwarz RI: Cell density regulates prolyl 4-hydroxylase activity independent of mRNA levels. Matrix Biol. 19:779–782. 2001. View Article : Google Scholar : PubMed/NCBI
4.	Gupta S, Kobayashi S, Phongkitkarun S, Broemeling LD and Kan Z: Effect of transcatheter hepatic arterial embolisation on angiogenesis in an animal model. Invest Radiol. 41:516–521. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Doffoel M, Bonnetain F, Bouche O, et al: Multicentre randomised phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Eur J Cancer. 44:528–538. 2008.
6.	Kudo M, Imanaka K, Chida N, et al: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 47:2117–2127. 2011. View Article : Google Scholar
7.	Britten CD, Gomes AS, Wainberg ZA, et al: Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer. 12:162012. View Article : Google Scholar
8.	Breinig M, Schirmacher P and Kern MA: Cyclooxygenase-2 (COX-2)-a therapeutic target in liver cancer? Curr Pharm Design. 13:3305–3315. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Wu T: Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev. 32:28–44. 2006. View Article : Google Scholar
10.	Zhao QT, Yue SQ, Cui Z, et al: Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sci. 80:484–492. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Cheng AS, Chan HL, To KF, et al: Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int J Oncol. 24:853–860. 2004.
12.	Reubi JC, Zimmermann A, Jonas S, et al: Regulatory peptide receptors in human hepatocellular carcinomas. Gut. 45:766–774. 1999. View Article : Google Scholar : PubMed/NCBI
13.	Xie Y, Chen S, Wang C and Tang C: SOM230 combined with celecoxib prolongs survival in nude mice with HepG-2 xenografts. Cancer Biol Ther. 12:86–92. 2011. View Article : Google Scholar : PubMed/NCBI
14.	Tong H, Li X, Zhang CL, et al: Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts. J Dig Dis. Oct 5–2012.(Epub ahead of print).
15.	Wu TH, Yu MC, Chen TC, et al: Encapsulation is a significant prognostic factor for better outcome in large hepatocellular carcinoma. J Surg Oncol. 105:85–90. 2012. View Article : Google Scholar
16.	Emile JF, Lemoine A, Azoulay D, Debuire B, Bismuth H and Reynes M: Histological, genomic and clinical heterogeneity of clear cell hepatocellular carcinoma. Histopathology. 38:225–231. 2001. View Article : Google Scholar : PubMed/NCBI
17.	Kashala LO, Conne B, Kalengayi MM, et al: Histopathologic features of hepatocellular carcinoma in Zaire. Cancer. 65:130–134. 1990. View Article : Google Scholar : PubMed/NCBI
18.	Lai CL, Wu PC, Lam KC and Todd D: Histologic prognostic indicators in hepatocellular carcinoma. Cancer. 44:1677–1683. 1979. View Article : Google Scholar : PubMed/NCBI
19.	Adamek HE, Spiethoff A, Kaumann V, et al: Primary clear cell carcinoma of noncirrhotic liver: immunohistochemical discrimination of hepatocellular and cholangiocellular origin. Dig Dis Sci. 43:33–38. 1998. View Article : Google Scholar
20.	Murakata LA, Ishak KG and Nzeako UC: Clear cell carcinoma of the liver: a comparative immunohistochemical study with renal clear cell carcinoma. Mod Pathol. 13:874–881. 2000. View Article : Google Scholar : PubMed/NCBI
21.	Liu Z, Ma W, Li H and Li Q: Clinicopathological and prognostic features of primary clear cell carcinoma of the liver. Hepatol Res. 38:291–299. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Iguchi T, Aishima S, Sanefuji K, et al: Both fibrous capsule formation and extracapsular penetration are powerful predictors of poor survival in human hepatocellular carcinoma: a histological assessment of 365 patients in Japan. Ann Surg Oncol. 16:2539–2546. 2009. View Article : Google Scholar
23.	Tanaka T, Yamanaka N, Oriyama T, Furukawa K and Okamoto E: Factors regulating tumor pressure in hepatocellular carcinoma and implications for tumor spread. Hepatology. 26:283–287. 1997. View Article : Google Scholar : PubMed/NCBI